Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands.

Renner A, Romanova J, Ferko B, Schmutz H, Nebolsin V, Müller M, Badorrek P, Marth K, Pohl W.

Pulm Pharmacol Ther. 2019 Oct 6:101852. doi: 10.1016/j.pupt.2019.101852. [Epub ahead of print]

PMID:
31597083
2.

Photocatalytic Reductive Formation of α-Tertiary Ethers from Ketals.

Rossolini T, Ferko B, Dixon DJ.

Org Lett. 2019 Aug 9. doi: 10.1021/acs.orglett.9b02273. [Epub ahead of print]

PMID:
31397159
3.

Total Synthesis of Berkeleylactone A.

Ferko B, Zeman M, Formica M, Veselý S, Doháňošová J, Moncol J, Olejníková P, Berkeš D, Jakubec P, Dixon DJ, Caletková O.

J Org Chem. 2019 Jun 7;84(11):7159-7165. doi: 10.1021/acs.joc.9b00850. Epub 2019 May 23.

PMID:
31081630
4.

A Novel Oral Glutarimide Derivative XC8 Suppresses Sephadex-Induced Lung Inflammation in Rats and Ovalbumin-induced Acute and Chronic Asthma in Guinea Pigs.

Ferko B, Romanova J, Rydlovskaya AV, Kromova TA, Proskurina OV, Amelina AN, Schmutz H, Renner A, Nebolsin VE.

Curr Pharm Biotechnol. 2019;20(2):146-156. doi: 10.2174/1389201020666190215103505.

PMID:
30767739
5.

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R.

PLoS One. 2015 Nov 12;10(11):e0143269. doi: 10.1371/journal.pone.0143269. eCollection 2015. No abstract available.

6.

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Jindra C, Huber B, Shafti-Keramat S, Wolschek M, Ferko B, Muster T, Brandt S, Kirnbauer R.

PLoS One. 2015 Sep 18;10(9):e0138722. doi: 10.1371/journal.pone.0138722. eCollection 2015. Erratum in: PLoS One. 2015;10(11):e0143269.

7.

Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection.

Tabynov K, Sansyzbay A, Kydyrbayev Z, Yespembetov B, Ryskeldinova S, Zinina N, Assanzhanova N, Sultankulova K, Sandybayev N, Khairullin B, Kuznetsova I, Ferko B, Egorov A.

Virol J. 2014 Apr 10;11:69. doi: 10.1186/1743-422X-11-69.

8.

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.

Morokutti A, Muster T, Ferko B.

Vaccine. 2014 Apr 7;32(17):1897-900. doi: 10.1016/j.vaccine.2014.02.009. Epub 2014 Feb 22.

PMID:
24560674
9.

Validation of the modified hemagglutination inhibition assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response.

Morokutti A, Redlberger-Fritz M, Nakowitsch S, Krenn BM, Wressnigg N, Jungbauer A, Romanova J, Muster T, Popow-Kraupp T, Ferko B.

J Clin Virol. 2013 Apr;56(4):323-30. doi: 10.1016/j.jcv.2012.12.002. Epub 2013 Jan 31.

PMID:
23375739
10.

Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice.

Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, Egorov A, Muster T, Seong B, Kweon MN, Song M, Czerkinsky C, Nguyen HH.

PLoS One. 2012;7(6):e39921. doi: 10.1371/journal.pone.0039921. Epub 2012 Jun 27.

11.

Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet.

Schiavone M, Fiume G, Caivano A, de Laurentiis A, Falcone C, Masci FF, Iaccino E, Mimmi S, Palmieri C, Pisano A, Pontoriero M, Rossi A, Scialdone A, Vecchio E, Andreozzi C, Trovato M, Rafay J, Ferko B, Montefiori D, Lombardi A, Morsica G, Poli G, Quinto I, Pavone V, de Berardinis P, Scala G.

Int J Mol Sci. 2012;13(5):5674-99. doi: 10.3390/ijms13055674. Epub 2012 May 10.

12.

[Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].

Romanovskaia-Roman'ko EA, Ferko B, Vyshemirskiĭ OI, Romanova IuR, Krenn B, Muster T, Grudinin MP, Lapin BA, Egorov AIu, Kiselev OI.

Vopr Virusol. 2011 Nov-Dec;56(6):19-22. Russian.

PMID:
22359944
13.

Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.

Krenn BM, Egorov A, Romanovskaya-Romanko E, Wolschek M, Nakowitsch S, Ruthsatz T, Kiefmann B, Morokutti A, Humer J, Geiler J, Cinatl J, Michaelis M, Wressnigg N, Sturlan S, Ferko B, Batishchev OV, Indenbom AV, Zhu R, Kastner M, Hinterdorfer P, Kiselev O, Muster T, Romanova J.

PLoS One. 2011 Apr 7;6(4):e18577. doi: 10.1371/journal.pone.0018577.

14.

Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.

Nakowitsch S, Wolschek M, Morokutti A, Ruthsatz T, Krenn BM, Ferko B, Ferstl N, Triendl A, Muster T, Egorov A, Romanova J.

Vaccine. 2011 Apr 27;29(19):3517-24. doi: 10.1016/j.vaccine.2011.02.100. Epub 2011 Mar 12.

PMID:
21406268
15.

Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis.

Krammer F, Schinko T, Messner P, Palmberger D, Ferko B, Grabherr R.

J Virol Methods. 2010 Jul;167(1):17-22. doi: 10.1016/j.jviromet.2010.03.003. Epub 2010 Mar 19.

16.

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

Krammer F, Nakowitsch S, Messner P, Palmberger D, Ferko B, Grabherr R.

Biotechnol J. 2010 Jan;5(1):17-23. doi: 10.1002/biot.200900267.

17.

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T.

J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428.

PMID:
20039806
18.

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A.

PLoS One. 2009 Jun 19;4(6):e5984. doi: 10.1371/journal.pone.0005984.

19.

Azidothymidine inhibits melanoma cell growth in vitro and in vivo.

Humer J, Ferko B, Waltenberger A, Rapberger R, Pehamberger H, Muster T.

Melanoma Res. 2008 Oct;18(5):314-21. doi: 10.1097/CMR.0b013e32830aaaa6.

PMID:
18781129
20.

Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine.

Gach JS, Quendler H, Ferko B, Katinger H, Kunert R.

Mol Biotechnol. 2008 Jun;39(2):119-25. doi: 10.1007/s12033-008-9054-7.

PMID:
18327550
21.

Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A.

J Virol. 2006 Dec;80(23):11621-7. Epub 2006 Sep 13.

22.

GMP production of liposomes--a new industrial approach.

Wagner A, Platzgummer M, Kreismayr G, Quendler H, Stiegler G, Ferko B, Vecera G, Vorauer-Uhl K, Katinger H.

J Liposome Res. 2006;16(3):311-9.

PMID:
16952884
23.

Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, Vinogradova T, Katinger H, Kiselev O, Egorov A.

Clin Vaccine Immunol. 2006 Aug;13(8):898-904.

24.

Virus-coated layer-by-layer colloids as a multiplex suspension array for the detection and quantification of virus-specific antibodies.

Toellner L, Fischlechner M, Ferko B, Grabherr RM, Donath E.

Clin Chem. 2006 Aug;52(8):1575-83. Epub 2006 May 25.

25.

Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein.

Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, Vinogradova TI, Katinger H, Kiselev OI, Egorov A.

Tuberculosis (Edinb). 2006 May-Jul;86(3-4):236-46.

PMID:
16677861
26.

Immunoglobulin G specifically binding plant N-glycans with high affinity could be generated in rabbits but not in mice.

Jin C, Bencúrová M, Borth N, Ferko B, Jensen-Jarolim E, Altmann F, Hantusch B.

Glycobiology. 2006 Apr;16(4):349-57. Epub 2005 Dec 21.

PMID:
16373330
27.

Establishment of a strategy for the rapid generation of a monoclonal antibody against the human protein SNEV (hNMP200) by flow-cytometric cell sorting.

Böhm E, Grillari J, Voglauer R, Gross S, Ernst W, Ferko B, Kunert R, Katinger H, Borth N.

J Immunol Methods. 2005 Dec 20;307(1-2):13-23. Epub 2005 Oct 10.

PMID:
16289093
28.

Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A.

J Virol. 2005 Aug;79(16):10672-7.

29.
30.

Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.

Lenz O, Dittmar MT, Wagner A, Ferko B, Vorauer-Uhl K, Stiegler G, Weissenhorn W.

J Biol Chem. 2005 Feb 11;280(6):4095-101. Epub 2004 Dec 1.

31.

Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes.

Ferko B, Stasakova J, Romanova J, Kittel C, Sereinig S, Katinger H, Egorov A.

J Virol. 2004 Dec;78(23):13037-45.

32.

Rescue of influenza virus expressing GFP from the NS1 reading frame.

Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, Wolkerstorfer A, Katinger H, Egorov A.

Virology. 2004 Jun 20;324(1):67-73.

33.

Live cold-adapted influenza A vaccine produced in Vero cell line.

Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A.

Virus Res. 2004 Jul;103(1-2):187-93.

PMID:
15163508
34.

Effect of a single mutation in neuraminidase on the properties of Influenza B virus isolates.

Katinger D, Romanova J, Ferko B, Fekete H, Egorov A.

Arch Virol. 2004 Jan;149(1):173-81. Epub 2003 Sep 22.

PMID:
14689282
35.

Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern.

Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, Bovin N, Lim W, Katinger H, Egorov A.

Virology. 2003 Mar 1;307(1):90-7.

36.

Reepithelialization of experimental scalds effected by topically applied superoxide dismutase: controlled animal studies.

Vorauer-Uhl K, Fürnschlief E, Wagner A, Ferko B, Katinger H.

Wound Repair Regen. 2002 Nov-Dec;10(6):366-71.

PMID:
12453140
37.

Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5.

Kunert RE, Weik R, Ferko B, Stiegler G, Katinger H.

AIDS. 2002 Mar 8;16(4):667-8.

PMID:
11873012
38.
39.

Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation.

Vorauer-Uhl K, Fürnschlief E, Wagner A, Ferko B, Katinger H.

Eur J Pharm Sci. 2001 Aug;14(1):63-7.

PMID:
11457651
40.

Dental wear and growth performance in steers fed sweetpotato cannery waste.

Rogers GM, Poore MH, Ferko BL, Brown TT, Deaton TG, Bawden JW.

J Am Vet Med Assoc. 1999 Mar 1;214(5):681-7.

PMID:
10088019
41.

Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract.

Ferko B, Katinger D, Grassauer A, Egorov A, Romanova J, Niebler B, Katinger H, Muster T.

J Infect Dis. 1998 Nov;178(5):1359-68.

PMID:
9780256
42.

Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells.

Egorov A, Brandt S, Sereinig S, Romanova J, Ferko B, Katinger D, Grassauer A, Alexandrova G, Katinger H, Muster T.

J Virol. 1998 Aug;72(8):6437-41.

43.

A host restriction-based selection system for influenza haemagglutinin transfectant viruses.

Grassauer A, Egorov AY, Ferko B, Romanova I, Katinger H, Muster T.

J Gen Virol. 1998 Jun;79 ( Pt 6):1405-9.

PMID:
9634082
44.

In vitro effects of an acidic by-product feed on bovine teeth.

Rogers GM, Poore MH, Ferko BL, Kusy RP, Deaton TG, Bawden JW.

Am J Vet Res. 1997 May;58(5):498-503.

PMID:
9140558
45.

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, Katinger H, Rüker F.

J Gen Virol. 1996 Sep;77 ( Pt 9):2001-8.

PMID:
8810996
46.

Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Muster T, Ferko B, Klima A, Purtscher M, Trkola A, Schulz P, Grassauer A, Engelhardt OG, García-Sástre A, Palese P, et al.

J Virol. 1995 Nov;69(11):6678-86.

47.

Parameters governing steam sterilization of deadlegs.

Young JH, Ferko BL, Gaber RP.

J Pharm Sci Technol. 1994 May-Jun;48(3):140-7.

PMID:
8069515
48.

Temperature profiles and sterilization within a dead-ended tube.

Young JH, Ferko BL.

J Parenter Sci Technol. 1992 Jul-Aug;46(4):117-23.

PMID:
1453280
49.

[Parvovirus infection of swine (literature review)].

Liebermann H, Hille G, Oehme G, Ferko B.

Arch Exp Veterinarmed. 1988 Nov;42(6):890-904. Review. German. No abstract available.

PMID:
2851296

Supplemental Content

Support Center